BlossomHill Therapeutics, Inc.
Price
Where the revenue goes
Loading the income statement flow…
Where the revenue comes from
Fundamentals
Loading key figures…
Insiders, analysts and people
All trades and changesLoading insiders, analysts and opinions…
Co se právě děje
AI souhrnAbout the company
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
- Website
- bhtherapeutics.com
- Country
- United States
- Fiscal year end
- 31. 12.
- Data since
- 7. 8. 2026